The abstract is read at the publisher; the summary is JClub's.
By 2026, 29 states and Washington, DC, enacted insulin out-of-pocket caps, covering an estimated 0.99 million adults with diabetes using insulin in state-regulated commercial plans.
- Why it matters: High insulin prices remain a barrier to diabetes management, and the study addresses how much state-level OOP cap laws actually protect commercially insured people.
- What they did: The authors compiled insulin OOP cap legislation enacted through 2026 and estimated eligible and exposed populations using public diabetes prevalence and health insurance coverage data.
- The result: An estimated 0.67 million adults with diabetes using insulin remain unprotected because they live in states without caps, and 2.2 million more are in federally regulated commercial plans outside state jurisdiction.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.